Hypoxia modulates the effect of dihydroartemisinin on endothelial cells

Biochemical Pharmacology

Volumn 82, Issue 5, 2011, Pages 476-484

  D'Alessandro, S ^a,e   Basilico, N ^a,e   Corbett, Y ^a,e   Scaccabarozzi, D ^a,e   Omodeo Sale F ^a,e   Saresella, M ^b   Marventano, I ^b   Vaillant, M ^c   Olliaro, P ^d   Taramelli, D ^a,e  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,10 DIMETHYL 7,8,15,16 TETRAOXADISPIRO[5.2.5.2]HEXADECANE; DEOXYDIHYDROARTEMISININ; DIHYDROARTEMISININ; DIHYDROARTEMISININ DERIVATIVE; MEMBRANE LIPID; PEROXIDE; TETRAOXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL HYPOXIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FLUORESCENCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPOXIA; LIPID ANALYSIS; LIPID PEROXIDATION; LOW DRUG DOSE; MICROVASCULAR ENDOTHELIAL CELL; OXIDATIVE STRESS; OXYGEN TENSION; PRIORITY JOURNAL;

EID: 79960906401     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.06.002     Document Type: Article

References (67)

1. Ward JP. Oxygen sensors in context. Biochim Biophys Acta 2008;1777:1-14.
2. Abidia A. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 2000;27:630. (Pubitemid 30436202)
3. Fraisl P, Mazzone M, Schmidt T, Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. Dev Cell 2009;16:167-79.
4. Germain S, Monnot C, Muller L, Eichmann A. Hypoxia-driven angiogenesis: role of tip cells and extracellular matrix scaffolding. Curr Opin Hematol 2010;17:245-51.
5. Cébe-Suarez S, Zehnder-Fjällman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 2006;63:601-15.
6. Hartmann G, Tschöp M, Fischer R, Bidlingmaier C, Riepl R, Tschöp K, et al. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and c-reactive protein. Cytokine 2000;12:246-52. (Pubitemid 30449882)
7. Gordon MS, Mendelson DS, Kato G. Tumor angiogenesis and novel antiangiogenic strategies. Int J Cancer 2010;126:1777-87.
8. Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010;13:16-28.
9. Karar J, Maity A. Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther 2009;8:1994-2001.
10. White NJ. Qinghaosu (Artemisinin): the price of success. Science 2008;320:330-4. (Pubitemid 351555649)
11. Efferth T. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin - from bench to bedside. Planta Med 2007;73:299-309. (Pubitemid 46910410)
12. Krishna S, Bustamante L, Haynes RK, Staines HM. Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 2008;29:520-7.
13. Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist Updat 2005;8:85-97. (Pubitemid 40797959)
14. Dell'Eva R, Pfeffer U, Vene R, Anfosso L, Forlani A, Albini A, et al. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 2004;68:2359-66. (Pubitemid 39535108)
15. Chen H-H, Li-Li Y, Shang-bin L. Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell. Cancer Lett 2004;211:163-73. (Pubitemid 38824630)
16. Wu XH, Zhou HJ, Lee J. Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion. Anticancer Drugs 2006;17:839-48. (Pubitemid 44310180)
17. Chen H-H, Zhou H-J, Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res 2003;48:231-6. (Pubitemid 36818928)
18. Chen H-H, Zhou H-J, Wang W-Q, Wu G-D. Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother Pharmacol 2004;V53:423-32. (Pubitemid 38553665)
19. D'Alessandro S, Gelati M, Basilico N, Parati EA, Haynes RK, Taramelli D. Differential effects on angiogenesis of two antimalarial compounds, dihydroartemisinin and artemisone: implications for embryotoxicity. Toxicology 2007;241:66-74. (Pubitemid 47599780)
20. Anfosso L, Efferth T, Albini A, Pfeffer U. Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J 2006;6:269-78. (Pubitemid 44137954)
21. O'Neill P, Posner G. A medicinal chemistry perspective on artemisinin and related endoperoxides. J Med Chem 2004;47:2945-64. (Pubitemid 38702690)
22. Meunier B, Robert A. Heme as trigger and target for trioxane-containing antimalarial drugs. Acc Chem Res 2010;43:1444-51.
23. Krishna S, Pulcini S, Fatih F, Staines H. Artemisinins and the biological basis for the PfATP6/SERCA hypothesis. Trends Parasitol 2010;26:517-23.
24. Haynes RK, Chan WC, Wong HN, Li KY, Wu WK, Fan KM, et al. Facile oxidation of leucomethylene blue and dihydroflavins by artemisinins: relationship with flavoenzyme function and antimalarial mechanism of action. ChemMedChem 2010;5:1282-99.
25. Haynes RK, Cheu K-W, Tang MM-K, Chen M-J, Guo Z-F, Guo Z-H, et al. Reactions of antimalarial peroxides with each of leucomethylene blue and dihydroflavins: flavin reductase and the cofactor model exemplified. Chem- MedChem 2011;6:279-91.
26. Holmgren A, Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun 2010;396:120-4.
27. Parapini S, Basilico N, Mondani M, Olliaro P, Taramelli D, Monti D. Evidence that haem iron in the malaria parasite is not needed for the antimalarial effects of artemisinin. FEBS Lett 2004;575:91-4. (Pubitemid 39242673)
28. Dondorp AM, Pongponratn E, White NJ. Reduced microcirculatory flow in severe falciparum malaria: pathophysiology and electron-microscopic pathology. Acta Trop 2004;89:309-17. (Pubitemid 38117067)
29. Lumb A. Nunn's applied respiratory physiology. Philadelphia: Butterworth Heinemann; 2005.
30. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992;99:683-90. (Pubitemid 23002027)
31. Vennerstrom JL, Fu HN, Ellis WY, Ager Jr AL, Wood JK, Andersen SL, et al. Dispiro-1,2,4,5-tetraoxanes: a new class of antimalarial peroxides. J Med Chem 1992;35:3023-7.
32. Taramelli D, Basilico N, De Palma AM, Saresella M, Ferrante P, Mussoni L, et al. The effect of synthetic malaria pigment (beta-haematin) on adhesion molecule expression and interleukin-6 production by human endothelial cells. Trans R Soc Trop Med Hyg 1998;92:57-62. (Pubitemid 28073731)
33. Wey HE, Pyron L, Woolery M. Essential fatty acid deficiency in cultured human keratinocytes attenuates toxicity due to lipid peroxidation. Toxicol Appl Pharmacol 1993;120:72-9. (Pubitemid 23156375)
34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
35. Mercer AE. The role of bioactivation in the pharmacology and toxicology of the artemisinin-based antimalarials. Curr Opin Drug Discov Devel 2009;12:125-32.
36. Firestone GL, Sundar SN. Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med 2009;11:e32.
37. Taramelli D, Recalcati S, Basilico N, Olliaro P, Cairo G. Macrophage preconditioning with synthetic malaria pigment reduces cytokine production via heme iron-dependent oxidative stress. Lab Invest 2000;80:1781-8. (Pubitemid 32012747)
38. Li Q, Cantilena LR, Leary KJ, Saviolakis GA, Miller RS, Melendez V, et al. Pharmacokinetic profiles of artesunate after single intravenous doses at 0.5, 1, 2, 4, and 8 mg/kg in healthy volunteers: a phase I study. Am J Trop Med Hyg 2009;81:615-21.
39. Newton PN, van Vugt M, Teja-Isavadharm P, Siriyanonda D, Rasameesoroj M, Teerapong P, et al. Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute falciparum malaria. Antimicrob Agents Chemother 2002;46:1125-7. (Pubitemid 34260366)
40. Zhou HJ, Zhang JL, Li A, Wang Z, Lou XE. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro. Cancer Chemother Pharmacol 2010;66:21-9.
41. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Micro 2009;7:864-74.
42. Olliaro PL, Haynes RK, Meunier B, Yuthavong Y. Possible modes of action of the artemisinin-type compounds. Trends Parasitol 2001;17:122-6. (Pubitemid 32422178)
43. Mercer AE, Maggs JL, Sun X-M, Cohen GM, Chadwick J, O'Neill PM, et al. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J Biol Chem 2007;282:9372-82. (Pubitemid 47104599)
44. Kumura N, Furukawa H, Onyango AN, Izumi M, Nakajima S, Ito H, et al. Different behavior of artemisinin and tetraoxane in the oxidative degradation of phospholipid. Chem Phys Lipids 2009;160:114-20.
45. Efferth T, Giaisi M, Merling A, Krammer PH, Li-Weber M. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One 2007;2:e693.
46. Wartenberg M, Wolf S, Budde P, Grunheck F, Acker H, Hescheler J, et al. The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. Lab Invest 2003;83:1647-55. (Pubitemid 37421105)
47. Berman PA, Adams PA. Artemisinin enhances heme-catalysed oxidation of lipid membranes. Free Radic Biol Med 1997;22:1283-8. (Pubitemid 27171971)
48. Schmuck G, Roehrdanz E, Haynes RK, Kahl R. Neurotoxic mode of action of artemisinin. Antimicrob Agents Chemother 2002;46:821-7. (Pubitemid 34157669)
49. Smith SL, Sadler CJ, Dodd CC, Edwards G, Ward SA, Park BK, et al. The role of glutathione in the neurotoxicity of artemisinin derivatives in vitro. Biochem Pharmacol 2001;61:409-16. (Pubitemid 32168222)
50. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 2004;287:R1014-30. (Pubitemid 39391043)
51. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000;87:179-83. (Pubitemid 30626423)
52. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008;10:1713-65.
53. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008;8:425-37. (Pubitemid 351744964)
54. Riganti C, Doublier S, Viarisio D, Miraglia E, Pescarmona G, Ghigo D, et al. Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression. Br J Pharmacol 2009;156:1054-66.
55. Huang XJ, Ma ZQ, Zhang WP, Lu YB, Wei EQ. Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. J Pharm Pharmacol 2007;59:849-56.
56. Jiao Y, Ge CM, Meng QH, Cao JP, Tong J, Fan SJ. Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin 2007;28:1045-56. (Pubitemid 47020494)
57. Liu WM, Gravett AM, Dalgleish AG. The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies. Int J Cancer 2010.
58. Willoughby Sr JA, Sundar SN, Cheung M, Tin AS, Modiano J, Firestone GL. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 2009;284:2203-13.
59. Lu JJ, Meng LH, Shankavaram UT, Zhu CH, Tong LJ, Chen G, et al. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol 2010;80:22-30.
60. Li PC, Lam E, Roos WP, Zdzienicka MZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res 2008;68:4347-51.
61. Marimpietri D, Nico B, Vacca A, Mangieri D, Catarsi P, Ponzoni M, et al. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene 2005;24:6785-95. (Pubitemid 41487037)
62. Tamura D, Arao T, Tanaka K, Kaneda H, Matsumoto K, Kudo K, et al. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition. Cancer Sci 2010;101:1403-8.
63. Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 2005;24:1188-202. (Pubitemid 40313920)
64. WHO. Assessment of the safety of artemisinin compounds in pregnancy. WHO/CDS/MAL/20903.1094; 2007.
65. Clark RL. Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reprod Toxicol 2009;28:285-96.
66. Longo M, Zanoncelli S, Manera D, Brughera M, Colombo P, Lansen J, et al. Effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos in vitro. Reprod Toxicol 2006;21:83-93. (Pubitemid 43048778)
67. Finaurini S, Ronzoni L, Colancecco A, Cattaneo A, Cappellini MD, Ward SA, et al. Selective toxicity of dihydroartemisinin on human CD34+ erythroid cell differentiation. Toxicology 2010;276:128-34.